Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (45)
Yasameen Muzahim, Ali Wakil, Mehak Bassi & Nikolaos Pyrsopoulos. (2024) Treatment of Primary Biliary Cholangitis including Transplantation. Clinics in Liver Disease 28:1, pages 103-114.
Crossref
Crossref
Jiaqiang Wu, Kangping Yang, Hancheng Fan, Meilin Wei & Qin Xiong. (2023) Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus. Frontiers in Endocrinology 14.
Crossref
Crossref
Yafei Xia, Shixin Yan, Yang Chang, Jiaoyang Yin, Hongyu Li & Shu Yan. (2022) Mechanism and Active Components of Qingre Lidan Tablets Alleviate Intrahepatic Cholestasis by Activating the Farnesoid X Receptor. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-13.
Crossref
Crossref
Xi-Ting Lv, Ruo-Hong Wang, Xiao-Ting Liu, Yu-Jing Ye, Xin-Yu Liu, Jing-Da Qiao & Guo-En Wang. (2022) Theacrine ameliorates experimental liver fibrosis in rats by lowering cholesterol storage via activation of the Sirtuin 3-farnesoid X receptor signaling pathway. Chemico-Biological Interactions 364, pages 110051.
Crossref
Crossref
Yunlong Xia, Xinyue Xu, Yongzhen Guo, Chen Lin, Xiaoming Xu, Fuyang Zhang, Miaomiao Fan, Tingting Qi, Congye Li, Guangyu Hu, Lu Peng, Shan Wang, Ling Zhang, Chunxu Hai, Rui Liu, Wenjun Yan & Ling Tao. (2022) Mesenchymal Stromal Cells Overexpressing Farnesoid X Receptor Exert Cardioprotective Effects Against Acute Ischemic Heart Injury by Binding Endogenous Bile Acids. Advanced Science 9:24.
Crossref
Crossref
Chuangzhen Lin, Bingqing Yu, Xuelian Liu, Lixin Chen, Zhaohui Zhang, Weixiang Ye, Hui Zhong, Wenke Bai, Yuping Yang & Biao Nie. (2022) Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse. Biomedicine & Pharmacotherapy 150, pages 112984.
Crossref
Crossref
Chuangzhen Lin, Bingqing Yu, Lixin Chen, Zhaohui Zhang, Weixiang Ye, Hui Zhong, Wenke Bai, Yuping Yang & Biao Nie. (2022) Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice. Frontiers in Pharmacology 13.
Crossref
Crossref
Alex Smith, Benjamin Giles & Richard J Aspinall. (2022) Primary biliary cholangitis: advances in understanding and management. British Journal of Hospital Medicine 83:3, pages 1-9.
Crossref
Crossref
Nadir Abbas, Mohammad Nabil Quraishi & Palak Trivedi. (2022) Emerging drugs for the treatment of primary sclerosing cholangitis. Current Opinion in Pharmacology 62, pages 23-35.
Crossref
Crossref
Chang Wang, Fei Peng, Bohua Zhong, Ying Shi, Xiaomei Wang, Xueyuan Jin & Junqi Niu. (2021) Metabolomic Analysis Reveals the Therapeutic Effects of MBT1805, a Novel Pan-Peroxisome Proliferator-Activated Receptor Agonist, on α-Naphthylisothiocyanate-Induced Cholestasis in Mice. Frontiers in Pharmacology 12.
Crossref
Crossref
S Nadir Abbas, David Jones, Yiannis Kallis, Laura Maher & Imran Patanwala. (2021) Primary biliary cholangitis: assessment and management strategies. Gastrointestinal Nursing 19:Sup4, pages S1-S24.
Crossref
Crossref
Adrian Dominik & Jan Stange. (2021) Similarities, Differences, and Potential Synergies in the Mechanism of Action of Albumin Dialysis Using the MARS Albumin Dialysis Device and the CytoSorb Hemoperfusion Device in the Treatment of Liver Failure. Blood Purification 50:1, pages 119-128.
Crossref
Crossref
Jin-nan Wu, Jian-rong Chen & Jin-liang Chen. (2020) Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases. Canadian Respiratory Journal 2020, pages 1-8.
Crossref
Crossref
Guofeng Ji, Lushun Ma, Haochen Yao, Sheng Ma, Xinghui Si, Yalin Wang, Xin Bao, Lili Ma, Fangfang Chen, Chong Ma, Leaf Huang, Xuedong Fang & Wantong Song. (2020) Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy. Acta Pharmaceutica Sinica B 10:11, pages 2171-2182.
Crossref
Crossref
Yanli Tong, Tony Marion, Georg Schett, Yubin Luo & Yi Liu. (2020) Microbiota and metabolites in rheumatic diseases. Autoimmunity Reviews 19:8, pages 102530.
Crossref
Crossref
Roger W Chapman & Kate D Lynch. (2020) Obeticholic acid—a new therapy in PBC and NASH. British Medical Bulletin 133:1, pages 95-104.
Crossref
Crossref
Yan-Li Hao, Zhao-Lian Bian, Lin-Ling Ju, Yuan Liu & Gang Qin. (2019) RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis. Digestive Diseases and Sciences 65:2, pages 470-479.
Crossref
Crossref
Vik Meadows, Lindsey Kennedy, Debjyoti Kundu, Gianfranco Alpini & Heather Francis. (2020) Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases. Frontiers in Medicine 7.
Crossref
Crossref
Ali Saeed, Jing Yang, Janette Heegsma, Albert K. Groen, Saskia W. C. van Mil, Coen C. Paulusma, Lu Zhou, Bangmao Wang & Klaas Nico Faber. (2019) Farnesoid X receptor and bile acids regulate vitamin A storage. Scientific Reports 9:1.
Crossref
Crossref
Laith Alrubaiy, George Mells, Steven Flack, Helen Bosomworth, Hayley Hutchings, John Williams & David Jones. (2019) PBC‐10: a short quality of life measure for clinical screening in primary biliary cholangitis. Alimentary Pharmacology & Therapeutics 50:11-12, pages 1223-1231.
Crossref
Crossref
Hiroshi Fukui. (2019) Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?. Diseases 7:4, pages 58.
Crossref
Crossref
Adnan Malik, Ani A. Kardashian, Kais Zakharia, Christopher L. Bowlus & James H. Tabibian. (2019) Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. Liver Research 3:2, pages 118-127.
Crossref
Crossref
Paul Manka, Amos Zeller & Wing-Kin Syn. (2019) Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 79:9, pages 903-927.
Crossref
Crossref
Omer Shahab, Mehmet Sayiner, James Paik, Sean Felix, Pegah Golabi & Zobair M. Younossi. (2019) Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States. Hepatology Communications 3:3, pages 356-364.
Crossref
Crossref
Benjamin Kirchweger & Judith M. Rollinger. 2019. Progress in the Chemistry of Organic Natural Products 110. Progress in the Chemistry of Organic Natural Products 110
239
271
.
Tanja M. Šarenac & Momir Mikov. (2018) Bile Acid Synthesis: From Nature to the Chemical Modification and Synthesis and Their Applications as Drugs and Nutrients. Frontiers in Pharmacology 9.
Crossref
Crossref
Gideon M Hirschfield, Jessica K Dyson, Graeme J M Alexander, Michael H Chapman, Jane Collier, Stefan Hübscher, Imran Patanwala, Stephen P Pereira, Collette Thain, Douglas Thorburn, Dina Tiniakos, Martine Walmsley, George Webster & David E J Jones. (2018) The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 67:9, pages 1568-1594.
Crossref
Crossref
Atsushi Tanaka, Patrick S.C. Leung & Merrill Eric Gershwin. (2018) The Genetics and Epigenetics of Primary Biliary Cholangitis. Clinics in Liver Disease 22:3, pages 443-455.
Crossref
Crossref
Chang Han. (2018) Update on FXR Biology: Promising Therapeutic Target?. International Journal of Molecular Sciences 19:7, pages 2069.
Crossref
Crossref
Xiang Jiang, Min Lian, Yanmei Li, Weici Zhang, Qixia Wang, Yiran Wei, Jun Zhang, Weihua Chen, Xiao Xiao, Qi Miao, Zhaolian Bian, Dekai Qiu, Jingyuan Fang, Aftab A. Ansari, Patrick S.C. Leung, Ross L. Coppel, Ruqi Tang, M. Eric Gershwin & Xiong Ma. (2018) The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7. Journal of Autoimmunity 90, pages 64-75.
Crossref
Crossref
Cen Guo, Carl LaCerte, Jeffrey E. Edwards, Kenneth R. Brouwer & Kim L. R. Brouwer. (2018) Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms. Journal of Pharmacology and Experimental Therapeutics 365:2, pages 413-421.
Crossref
Crossref
Kais Zakharia, Anilga Tabibian, Keith D. Lindor & James H. Tabibian. (2018) Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. Liver International 38:3, pages 399-411.
Crossref
Crossref
Carlo Selmi & M. Eric Gershwin. (2017) Chronic Autoimmune Epithelitis in Sjögren’s Syndrome and Primary Biliary Cholangitis: A Comprehensive Review. Rheumatology and Therapy 4:2, pages 263-279.
Crossref
Crossref
Yasmeen M. Attia, Rasha A. Tawfiq, Aya A. Ali & Mohamed M. Elmazar. (2017) The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway. Scientific Reports 7:1.
Crossref
Crossref
Zhihui Zheng, Zanmei Zhao, Shuqiang Li, Xinhua Lu, Mengxi Jiang, Jie Lin, Yunqi An, Yang Xie, Meishu Xu, Wenbin Shen, Grace L. Guo, Yixian Huang, Song Li, Xuexia Zhang & Wen Xie. (2017) Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor. Molecular Pharmacology 92:4, pages 425-436.
Crossref
Crossref
Deirdre A Kelly. (2017) Paediatric liver disease: lessons for adult practice. The Lancet Gastroenterology & Hepatology 2:6, pages 390-392.
Crossref
Crossref
Antonio Molinaro & Hanns-Ulrich Marschall. (2017) Why Doesn’t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?. Current Hepatology Reports 16:2, pages 119-123.
Crossref
Crossref
Stephanie Hucke, Martin Herold, Marie Liebmann, Nicole Freise, Maren Lindner, Ann-Katrin Fleck, Stefanie Zenker, Stephanie Thiebes, Juncal Fernandez-Orth, Dorothea Buck, Felix Luessi, Sven G. Meuth, Frauke Zipp, Bernhard Hemmer, Daniel Robert Engel, Johannes Roth, Tanja Kuhlmann, Heinz Wiendl & Luisa Klotz. (2016) The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion. Acta Neuropathologica 132:3, pages 413-431.
Crossref
Crossref
Xavier Verhelst, Anja Geerts & Hans Van Vlierberghe. (2016) Cirrhosis: Reviewing the Literature and Future Perspectives. EMJ Hepatology, pages 111-117.
Crossref
Crossref
Zhi Qing Yuan & Ke Wei Li. (2016) Role of farnesoid X receptor in cholestasis. Journal of Digestive Diseases 17:8, pages 501-509.
Crossref
Crossref
C. Daniel De Magalhaes Filho, Michael Downes & Ron Evans. (2016) Bile Acid Analog Intercepts Liver Fibrosis. Cell 166:4, pages 789.
Crossref
Crossref
Peggy P. Ho & Lawrence Steinman. (2016) Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences 113:6, pages 1600-1605.
Crossref
Crossref
Jae Man Lee. (2016) Transcriptional coordination of hepatic autophagy by nutrient-sensing nuclear receptor PPARα and FXR. Annals of Pediatric Endocrinology & Metabolism 21:4, pages 193.
Crossref
Crossref
Ying-Qiu Huang. (2016) Recent advances in the diagnosis and treatment of primary biliary cholangitis. World Journal of Hepatology 8:33, pages 1419.
Crossref
Crossref
Ruchi Bansal, Beata Nagórniewicz & Jai Prakash. (2016) Clinical Advancements in the Targeted Therapies against Liver Fibrosis. Mediators of Inflammation 2016, pages 1-16.
Crossref
Crossref